Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How do I taper patients off corticosteroids after they respond to Omvoh® (mirikizumab)?
This response provides recommended schedule for tapering oral corticosteroids in eligible patients in the LUCENT clinical trial program.
Patients Eligible for Corticosteroid Tapering
Patients who entered the induction study, LUCENT-1, receiving corticosteroid therapy for the treatment of their ulcerative colitis and achieved clinical response with mirikizumab began corticosteroid tapering at week 0 of LUCENT-2.1
Patients who did not achieve clinical response with mirikizumab in the ulcerative colitis induction study, LUCENT-1, and received extended induction therapy with intravenous (IV) mirikizumab in the maintenance study, LUCENT-2, began corticosteroid tapering
- if clinical response was achieved at week 12 of extended induction, or
- if the patient experienced symptomatic improvement, based on the investigator's opinion, at any time after initiating extended induction dosing.1
Corticosteroid Tapering Procedure
Oral Corticosteroids Other Than Budesonide or Beclomethasone
shows the recommended schedule for tapering oral corticosteroid therapy other than budesonide extended release tablets (budesonide MMX) or beclomethasone dipropionate (gastro-resistant prolonged release tablet).1
If the oral corticosteroid dose is...
>10 mg/day prednisone or equivalent
taper daily dose by 5 mg/week until receiving 10 mg/day, and then continue tapering at 2.5 mg/week until 0 mg/day.
≤10 mg/day prednisone or equivalent
taper daily dose by 2.5 mg/week until 0 mg/day.
aOther than budesonide extended release tablets or beclomethasone dipropionate.
The recommended schedule for tapering oral budesonide extended release tablets (budesonide MMX) 9 mg/day is to reduce tablets to 9 mg every other day for 2 weeks, followed by 9 mg every third day for 2 weeks, and then discontinue.1
The recommended schedule for tapering oral beclomethasone dipropionate (gastroresistant prolonged-release tablet) 5 mg/day is to reduce tablets to 5 mg every other day for 4 weeks, and then discontinue.1
Recurrence of Clinical Symptoms During Corticosteroid Taper
In the LUCENT clinical trial program, if a patient experienced recurrence of clinical symptoms during the corticosteroid taper,
- the taper could be paused, and/or
- the corticosteroid dose could be increased to the original dose but not be greater than the dose at induction baseline.1
Attempts to reinitiate the corticosteroid taper were to begin within 2 weeks of the interruption.1
1D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. Published online June 29, 2023. https://doi.org/10.1056/NEJMoa2207940
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 30 May 2023